Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych VivasGeneral adult psychiatry — personality disorders

Psych Vivas · General adult psychiatry — personality disorders

Borderline personality disorder — structured clinical viva

Fellowship viva covering BPD diagnosis and bipolar differential, crisis risk, DBT/MBT/GPM evidence, limited pharmacotherapy, LABILE, and anti-nihilism longitudinal data.

clinical
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
You are the psychiatry registrar. A 29-year-old man with recurrent self-harm, unstable relationships, and affective instability is referred after a third ED presentation in a month. The ED consultant asks whether he 'just needs a mood stabiliser' and whether personality disorder is 'untreatable.' Discuss diagnosis, differentials, risk formulation, psychotherapy evidence, and a rational approach to medication.

Interpretation

Reveal interpretation

This is a recurrent crisis presentation consistent with borderline personality disorder, not a mandate for automatic mood-stabiliser initiation. Confirm operational criteria (DSM ≥5/9 or ICD-11 severity + borderline pattern), take a longitudinal history, and actively screen for bipolar episodes (duration, sleep need, energy), substances, PTSD, ADHD and depression. Risk formulation must separate chronic elevated self-harm risk from acute escalations after interpersonal triggers, with means restriction and a written safety plan.[2][4]

Psychotherapy is first-line. Name a model fully: DBT structure and hierarchy; or MBT mentalizing focus; or schema/TFP; or GPM/structured clinical management when specialised DBT is unavailable. McMain showed DBT and GPM both improved outcomes — structure beats nihilism.[1][2]

Medication. Cochrane evidence does not support a disease-modifying drug for BPD. LABILE showed lamotrigine not superior to placebo for core BPD. Treat comorbidity; any symptom-targeted agent needs a target symptom and review/stop date. Do not answer the ED question with lifelong polypharmacy.[3][5]

Prognosis. CLPS/MSAD-style longitudinal data support substantial symptomatic improvement over years for many people — “untreatable” is false and harmful.[4]

Key points

Structure over stigma

Specialised psychotherapy or structured clinical management is the core treatment pathway.

LABILE kills reflexive lamotrigine

Lamotrigine is not first-line disease-modifying therapy for BPD.

Hope is evidence-based

Longitudinal studies show many patients improve symptomatically over years.
[1] [3] [4]

References

  1. [1]McMain SF, Links PS, Gnam WH, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder Am J Psychiatry, 2009.PMID 19755574
  2. [2]Cristea IA, Gentili C, Cotet CD, et al. Efficacy of Psychotherapies for Borderline Personality Disorder: A Systematic Review and Meta-analysis JAMA Psychiatry, 2017.PMID 28249086
  3. [3]Crawford MJ, Sanatinia R, Barrett B, et al. The Clinical Effectiveness and Cost-Effectiveness of Lamotrigine in Borderline Personality Disorder: A Randomized Placebo-Controlled Trial Am J Psychiatry, 2018.PMID 29621901
  4. [4]Gunderson JG, Stout RL, McGlashan TH, et al. Ten-year course of borderline personality disorder: psychopathology and function from the Collaborative Longitudinal Personality Disorders study Arch Gen Psychiatry, 2011.PMID 21464343
  5. [5]Stoffers-Winterling JM, Storebø OJ, Pereira Ribeiro J, et al. Pharmacological interventions for people with borderline personality disorder Cochrane Database Syst Rev, 2022.PMID 36375174